Core Viewpoint - Meidida Medical, focused on tumor interventional therapy, has completed a multi-million A+ round financing to accelerate the development and clinical promotion of innovative medical devices for tumor treatment [2][15]. Industry Background - Tumor interventional therapy is gaining clinical attention due to its minimally invasive and precise nature, with techniques like thermal ablation becoming important alternatives for solid tumors such as liver, lung, and kidney cancers [3]. - Microwave ablation (MWA) is a mature thermal ablation method that uses microwave energy to induce heat in tumor tissues, leading to coagulative necrosis, particularly suitable for patients who cannot tolerate surgery. MWA offers advantages over traditional radiofrequency ablation, including faster heating, larger ablation areas, and reduced thermal loss [3]. Company Introduction - Meidida Medical is a high-tech medical company specializing in the research and industrialization of tumor interventional therapy devices, aiming to address clinical safety, efficiency, and complication risks associated with traditional techniques [6]. Core Products and Technology Introduction - The coaxial puncture thermal coagulation needle integrates biopsy and hemostasis in one device, significantly reducing bleeding risks and complications while enhancing operational safety and reducing post-operative care costs. This product is expected to enter the innovative channel for rapid registration and market launch by 2025 [9][10]. - The 5.8GHz high-frequency microwave ablation needle, recognized in Shanghai's "New and Excellent Drug and Device" catalog, offers faster energy transmission and better control over the ablation area compared to traditional systems. This positions Meidida Medical's platform as a competitive solution for treating various solid tumors, with significant potential to replace imported devices in the domestic market [13][14]. Conclusion - As minimally invasive tumor treatment becomes mainstream, domestic interventional device manufacturers like Meidida Medical are expected to reduce reliance on imports, lower patient costs, and improve clinical accessibility. The recent financing will accelerate the company's technology transfer and industrialization process, marking a new development phase for domestic tumor interventional devices [15].

Core Viewpoint - The Hengqin Guangdong-Macao Deep Cooperation Zone has made significant progress in promoting Macao's economic diversification and integration with Hengqin over the past four years, focusing on institutional innovation, industrial collaboration, and the integration of livelihoods [2][8]. Policy Support - The establishment of the cooperation zone has led to the relocation of companies like Zhenjiankang Medical Technology to Hengqin, benefiting from favorable policies and support [3]. - As of July 2023, there are nearly 60,000 operating entities in the cooperation zone, with Macao-funded enterprises increasing by 57.49% since its inception [3]. Innovation Empowerment - The establishment of the Zhuhai Macao University Science Research Institute has facilitated cross-border research and development, enhancing the integration of Macao's research capabilities with Hengqin's industrial advantages [5][6]. - New regulations have been introduced to facilitate cross-border practice for Macao medical and legal professionals, with 1,669 professionals already practicing in the cooperation zone as of July 2023 [6]. Livelihood Integration - The "Macao New Neighborhood" project has been developed to provide comprehensive living services for Macao residents, with increasing numbers choosing to reside there [7]. - As of June 2023, the number of Macao residents living in the cooperation zone reached 23,749, a year-on-year increase of 30.1%, while those employed in the zone reached 5,762, up 14.1% [8].

Group 1: Company Developments - Hengqin Bihua Medical Laboratory successfully passed the ISO15189 accreditation site review, indicating that its quality management system and testing capabilities meet international standards [5] - Zhenjiankang Company received NMPA Class III medical device registration for two innovative products, bringing its total to seven Class III and four Class II medical device registrations [6] - Guangdong Taiwen Biological Engineering Co., Ltd. obtained a Class II medical device production license, marking compliance with national regulatory requirements in the field of in vitro diagnostic reagents [7] Group 2: Industry Initiatives - The dual-currency payment pilot program has expanded to six key commercial areas in Hengqin, facilitating small payments in both RMB and MOP, enhancing consumer experience [8] - The revised management measures for the Hengqin Guangdong-Macao Deep Cooperation Zone government investment fund were published, effective from August 13, 2025, focusing on key industry projects [9] - The newly issued support measures for financing development of small and micro enterprises in Hengqin include interest subsidies and risk compensation, with a maximum single financing risk compensation of 7.2 million yuan [10][11]